Abstract
Antibiotics are widely used during pregnancy. Recent epidemiological studies suggest that maternal exposure to antibiotics during pregnancy is associated with increased risks of various diseases in offspring; host-microbiome interactions are considered to be involved in pathogenesis, as antibiotic-induced perturbations (dysbiosis) of the maternal microbiome can be transmitted to offspring. We reviewed the current status of antibiotic usage during pregnancy, transmission of maternal antibiotic-induced dysbiosis to offspring, and several diseases in offspring reported to be associated with maternal antibiotic exposure. Antibiotics must be properly used when necessary. While the adverse effect of maternal antibiotic exposure during pregnancy on the health of offspring has been demonstrated by several studies, more robust clinical evidence is necessary to define the best practice for antibiotic use during pregnancy. Epidemiologic studies have limitations in establishing causal links beyond associations; animal studies provide benefits in examining these links, however, microbiomes, gestation courses, and aging vary between host species. Understanding the underlying mechanisms of epidemiologic findings as well as the healthy microbiome during pregnancy and early life in humans would contribute to developing future microbial interventions for restoring antibiotic-induced dysbiosis during pregnancy.

Similar content being viewed by others
References
Gestels T, Vandenplas Y. Prenatal and perinatal antibiotic exposure and long-term outcome. Pediatr Gastroenterol Hepatol Nutr. 2023;26:135–45. https://doi.org/10.5223/pghn.2023.26.3.135.
Ortqvist AK, Lundholm C, Halfvarson J, et al. Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study. Gut. 2019;68:218–25. https://doi.org/10.1136/gutjnl-2017-314352.
Alhasan MM, Cait AM, Heimesaat MM, et al. Antibiotic use during pregnancy increases offspring asthma severity in a dose-dependent manner. Allergy. 2020;75:1979–90. https://doi.org/10.1111/all.14234.
Miyoshi J, Bobe AM, Miyoshi S, et al. Peripartum antibiotics promote gut dysbiosis, loss of immune tolerance, and inflammatory bowel disease in genetically prone offspring. Cell Rep. 2017;20:491–504. https://doi.org/10.1016/j.celrep.2017.06.060.
Miyoshi J, Lee STM, Kennedy M, et al. Metagenomic alterations in gut microbiota precede and predict onset of colitis in the IL10 gene-deficient murine model. Cell Mol Gastroenterol Hepatol. 2021;11:491–502. https://doi.org/10.1016/j.jcmgh.2020.08.008.
Miyoshi J, Miyoshi S, Delmont TO, et al. Early-life microbial restitution reduces colitis risk promoted by antibiotic-induced gut dysbiosis in interleukin 10(-/-) mice. Gastroenterology. 2021;161:940-52 e15. https://doi.org/10.1053/j.gastro.2021.05.054.
Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22:1079–89. https://doi.org/10.1038/nm.4185.
Hou K, Wu ZX, Chen XY, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7:135. https://doi.org/10.1038/s41392-022-00974-4.
Goodrich JK, Waters JL, Poole AC, et al. Human genetics shape the gut microbiome. Cell. 2014;159:789–99. https://doi.org/10.1016/j.cell.2014.09.053.
Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105–8. https://doi.org/10.1126/science.1208344.
David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–63. https://doi.org/10.1038/nature12820.
Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222–7. https://doi.org/10.1038/nature11053.
Buford TW. (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease. Microbiome. 2017;5:80. https://doi.org/10.1186/s40168-017-0296-0.
Afzaal M, Saeed F, Shah YA, et al. Human gut microbiota in health and disease: unveiling the relationship. Front Microbiol. 2022;13: 999001. https://doi.org/10.3389/fmicb.2022.999001.
Tamburini S, Shen N, Wu HC, et al. The microbiome in early life: implications for health outcomes. Nat Med. 2016;22:713–22. https://doi.org/10.1038/nm.4142.
Underwood MA, Mukhopadhyay S, Lakshminrusimha S, et al. Neonatal intestinal dysbiosis. J Perinatol. 2020;40:1597–608. https://doi.org/10.1038/s41372-020-00829-2.
Miyoshi J, Hisamatsu T. The impact of maternal exposure to antibiotics on the development of child gut microbiome. Immunol Med. 2022;45:63–8. https://doi.org/10.1080/25785826.2021.1963189.
Backhed F, Roswall J, Peng Y, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 2015;17:690–703. https://doi.org/10.1016/j.chom.2015.04.004.
Ferretti P, Pasolli E, Tett A, et al. Mother-to-infant microbial transmission from different body sites shapes the developing infant gut microbiome. Cell Host Microbe. 2018;24:133-45 e5. https://doi.org/10.1016/j.chom.2018.06.005.
Martinez I, Maldonado-Gomez MX, Gomes-Neto JC, et al. Experimental evaluation of the importance of colonization history in early-life gut microbiota assembly. Elife. 2018. https://doi.org/10.7554/eLife.36521.
Sprockett D, Fukami T, Relman DA. Role of priority effects in the early-life assembly of the gut microbiota. Nat Rev Gastroenterol Hepatol. 2018;15:197–205. https://doi.org/10.1038/nrgastro.2017.173.
Broe A, Pottegard A, Lamont RF, et al. Increasing use of antibiotics in pregnancy during the period 2000–2010: prevalence, timing, category, and demographics. BJOG. 2014;121:988–96. https://doi.org/10.1111/1471-0528.12806.
de Jonge L, Bos HJ, van Langen IM, et al. Antibiotics prescribed before, during and after pregnancy in the Netherlands: a drug utilization study. Pharmacoepidemiol Drug Saf. 2014;23:60–8. https://doi.org/10.1002/pds.3492.
Trinh NTH, Hjorth S, Nordeng HME. Use of interrupted time-series analysis to characterise antibiotic prescription fills across pregnancy: a Norwegian nationwide cohort study. BMJ Open. 2021;11: e050569. https://doi.org/10.1136/bmjopen-2021-050569.
Tran A, Zureik M, Sibiude J, et al. Prevalence and associated factors of antibiotic exposure during pregnancy in a large French population-based study during the 2010–19 period. J Antimicrob Chemother. 2023;78:2535–43. https://doi.org/10.1093/jac/dkad266.
Okoshi K, Sakurai K, Yamamoto M, et al. Maternal antibiotic exposure and childhood allergies: the Japan environment and children’s Study. J Allergy Clin Immunol Glob. 2023;2: 100137. https://doi.org/10.1016/j.jacig.2023.100137.
Nakitanda AO, Kieler H, Odsbu I, et al. In-utero antibiotic exposure and subsequent infections in infancy: a register-based cohort study with sibling analysis. Am J Obstet Gynecol MFM. 2023;5: 100860. https://doi.org/10.1016/j.ajogmf.2023.100860.
Martinez de Tejada B. Antibiotic use and misuse during pregnancy and delivery: benefits and risks. Int J Environ Res Public Health. 2014;11:7993–8009. https://doi.org/10.3390/ijerph110807993.
Baltimore RS, Huie SM, Meek JI, et al. Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics. 2001;108:1094–8. https://doi.org/10.1542/peds.108.5.1094.
Lyytikainen O, Nuorti JP, Halmesmaki E, et al. Invasive group B streptococcal infections in Finland: a population-based study. Emerg Infect Dis. 2003;9:469–73. https://doi.org/10.3201/eid0904.020481.
Heath PT, Balfour G, Weisner AM, et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet. 2004;363:292–4. https://doi.org/10.1016/S0140-6736(03)15389-5.
Kenyon SL, Taylor DJ, Tarnow-Mordi W, et al. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group Lancet. 2001;357:979–88. https://doi.org/10.1016/s0140-6736(00)04233-1.
Kenyon SL, Taylor DJ, Tarnow-Mordi W, et al. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group Lancet. 2001;357:989–94. https://doi.org/10.1016/s0140-6736(00)04234-3.
Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet. 2008;372:1319–27. https://doi.org/10.1016/S0140-6736(08)61203-9.
Wampach L, Heintz-Buschart A, Fritz JV, et al. Birth mode is associated with earliest strain-conferred gut microbiome functions and immunostimulatory potential. Nat Commun. 2018;9:5091. https://doi.org/10.1038/s41467-018-07631-x.
Yassour M, Jason E, Hogstrom LJ, et al. Strain-level analysis of mother-to-child bacterial transmission during the first few months of life. Cell Host Microbe. 2018;24(146–54): e4. https://doi.org/10.1016/j.chom.2018.06.007.
Aagaard K, Ma J, Antony KM, et al. The placenta harbors a unique microbiome. Sci Transl Med. 2014;6:237ra65. https://doi.org/10.1126/scitranslmed.3008599.
Ardissone AN, de la Cruz DM, Davis-Richardson AG, et al. Meconium microbiome analysis identifies bacteria correlated with premature birth. PLoS One. 2014;9: e90784. https://doi.org/10.1371/journal.pone.0090784.
Dong XD, Li XR, Luan JJ, et al. Bacterial communities in neonatal feces are similar to mothers’ placentae. Can J Infect Dis Med Microbiol. 2015;26:90–4. https://doi.org/10.1155/2015/737294.
Hansen R, Scott KP, Khan S, et al. First-pass meconium samples from healthy term vaginally-delivered neonates: an analysis of the microbiota. PLoS One. 2015;10: e0133320. https://doi.org/10.1371/journal.pone.0133320.
Collado MC, Rautava S, Aakko J, et al. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci Rep. 2016;6:23129. https://doi.org/10.1038/srep23129.
Seferovic MD, Pace RM, Carroll M, et al. Visualization of microbes by 16S in situ hybridization in term and preterm placentas without intraamniotic infection. Am J Obstet Gynecol. 2019;221(146):e1–23. https://doi.org/10.1016/j.ajog.2019.04.036.
He Q, Kwok LY, Xi X, et al. The meconium microbiota shares more features with the amniotic fluid microbiota than the maternal fecal and vaginal microbiota. Gut Microbes. 2020;12:1794266. https://doi.org/10.1080/19490976.2020.1794266.
Chu DM, Ma J, Prince AL, et al. Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery. Nat Med. 2017;23:314–26. https://doi.org/10.1038/nm.4272.
Shao Y, Forster SC, Tsaliki E, et al. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. Nature. 2019;574:117–21. https://doi.org/10.1038/s41586-019-1560-1.
Dominguez-Bello MG, De Jesus-Laboy KM, Shen N, et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med. 2016;22:250–3. https://doi.org/10.1038/nm.4039.
Rodriguez JM, Murphy K, Stanton C, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015;26:26050. https://doi.org/10.3402/mehd.v26.26050.
Azad MB, Konya T, Persaud RR, et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG. 2016;123:983–93. https://doi.org/10.1111/1471-0528.13601.
Coker MO, Hoen AG, Dade E, et al. Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study. BJOG. 2020;127:217–27. https://doi.org/10.1111/1471-0528.15799.
Nogacka A, Salazar N, Suarez M, et al. Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates. Microbiome. 2017;5:93. https://doi.org/10.1186/s40168-017-0313-3.
Dierikx TH, Visser DH, Benninga MA, et al. The influence of prenatal and intrapartum antibiotics on intestinal microbiota colonisation in infants: a systematic review. J Infect. 2020;81:190–204. https://doi.org/10.1016/j.jinf.2020.05.002.
Zimmermann P, Curtis N. Effect of intrapartum antibiotics on the intestinal microbiota of infants: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2020;105:201–8. https://doi.org/10.1136/archdischild-2018-316659.
Zhou P, Zhou Y, Liu B, et al. Perinatal antibiotic exposure affects the transmission between maternal and neonatal microbiota and is associated with early-onset sepsis. mSphere. 2020. https://doi.org/10.1128/mSphere.00984-19.
Tisseyre M, Collier M, Beeker N, et al. In utero exposure to antibiotics and risk of serious infections in the first year of life. Drug Saf. 2024. https://doi.org/10.1007/s40264-024-01401-z.
Miller JE, Wu C, Pedersen LH, et al. Maternal antibiotic exposure during pregnancy and hospitalization with infection in offspring: a population-based cohort study. Int J Epidemiol. 2018;47:561–71. https://doi.org/10.1093/ije/dyx272.
Pedersen TM, Stokholm J, Thorsen J, et al. Antibiotics in pregnancy increase children’s risk of otitis media and ventilation tubes. J Pediatr. 2017;183(153–8): e1. https://doi.org/10.1016/j.jpeds.2016.12.046.
Cunha A, Santos AC, Medronho RA, et al. Use of antibiotics during pregnancy is associated with infection in children at four years of age in Portugal. Acta Paediatr. 2021;110:1911–5. https://doi.org/10.1111/apa.15733.
Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics. 2012;130:e794-803. https://doi.org/10.1542/peds.2011-3886.
Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol. 2014;109:1728–38. https://doi.org/10.1038/ajg.2014.246.
Mor A, Antonsen S, Kahlert J, et al. Prenatal exposure to systemic antibacterials and overweight and obesity in Danish schoolchildren: a prevalence study. Int J Obes (Lond). 2015;39:1450–5. https://doi.org/10.1038/ijo.2015.129.
Mueller NT, Whyatt R, Hoepner L, et al. Prenatal exposure to antibiotics, cesarean section and risk of childhood obesity. Int J Obes (Lond). 2015;39:665–70. https://doi.org/10.1038/ijo.2014.180.
Cassidy-Bushrow AE, Burmeister C, Havstad S, et al. Prenatal antimicrobial use and early-childhood body mass index. Int J Obes (Lond). 2018;42:1–7. https://doi.org/10.1038/ijo.2017.205.
Wang B, Liu J, Zhang Y, et al. Prenatal exposure to antibiotics and risk of childhood obesity in a multicenter cohort study. Am J Epidemiol. 2018;187:2159–67. https://doi.org/10.1093/aje/kwy122.
Poulsen MN, Pollak J, Bailey-Davis L, et al. Associations of prenatal and childhood antibiotic use with child body mass index at age 3 years. Obesity (Silver Spring). 2017;25:438–44. https://doi.org/10.1002/oby.21719.
Jess T, Morgen CS, Harpsoe MC, et al. Antibiotic use during pregnancy and childhood overweight: a population-based nationwide cohort study. Sci Rep. 2019;9:11528. https://doi.org/10.1038/s41598-019-48065-9.
Baron R, Taye M, Besseling-van der Vaart I, et al. The relationship of prenatal and infant antibiotic exposure with childhood overweight and obesity: a systematic review. J Dev Orig Health Dis. 2020;11:335–49. https://doi.org/10.1017/S2040174419000722.
Stensballe LG, Simonsen J, Jensen SM, et al. Use of antibiotics during pregnancy increases the risk of asthma in early childhood. J Pediatr. 2013;162(832–8): e3. https://doi.org/10.1016/j.jpeds.2012.09.049.
Baron R, Taye M, der Vaart IB, et al. The relationship of prenatal antibiotic exposure and infant antibiotic administration with childhood allergies: a systematic review. BMC Pediatr. 2020;20:312. https://doi.org/10.1186/s12887-020-02042-8.
Cait A, Wedel A, Arntz JL, et al. Prenatal antibiotic exposure, asthma, and the atopic march: a systematic review and meta-analysis. Allergy. 2022;77:3233–48. https://doi.org/10.1111/all.15404.
Turi KN, Gebretsadik T, Ding T, et al. Dose, timing, and spectrum of prenatal antibiotic exposure and risk of childhood asthma. Clin Infect Dis. 2021;72:455–62. https://doi.org/10.1093/cid/ciaa085.
Metzler S, Frei R, Schmausser-Hechfellner E, et al. Association between antibiotic treatment during pregnancy and infancy and the development of allergic diseases. Pediatr Allergy Immunol. 2019;30:423–33. https://doi.org/10.1111/pai.13039.
Zhong Y, Zhang Y, Wang Y, et al. Maternal antibiotic exposure during pregnancy and the risk of allergic diseases in childhood: a meta-analysis. Pediatr Allergy Immunol. 2021;32:445–56. https://doi.org/10.1111/pai.13411.
Wohl DL, Curry WJ, Mauger D, et al. Intrapartum antibiotics and childhood atopic dermatitis. J Am Board Fam Med. 2015;28:82–9. https://doi.org/10.3122/jabfm.2015.01.140017.
Timm S, Schlunssen V, Olsen J, et al. Prenatal antibiotics and atopic dermatitis among 18-month-old children in the Danish national birth cohort. Clin Exp Allergy. 2017;47:929–36. https://doi.org/10.1111/cea.12916.
Hamad AF, Alessi-Severini S, Mahmud SM, et al. Prenatal antibiotics exposure and the risk of autism spectrum disorders: a population-based cohort study. PLoS One. 2019;14: e0221921. https://doi.org/10.1371/journal.pone.0221921.
Nitschke AS, do Valle HA, Vallance BA, et al. Association between prenatal antibiotic exposure and autism spectrum disorder among term births: a population-based cohort study. Paediatr Perinat Epidemiol. 2023;37:516–26. https://doi.org/10.1111/ppe.12972.
Lin YC, Lin CH, Lin MC. The association of prenatal antibiotic use with attention deficit and autism spectrum disorders: a nationwide cohort study. Children (Basel). 2023. https://doi.org/10.3390/children10071128.
Acknowledgements
We thank Lisa Oberding, MSc, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Jun Miyoshi has received grant support from AbbVie GK; and received consulting and lecture fees from EA Pharma Co., Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Jansen Asia Pacific Pte. Ltd., Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, JIMRO Co., Miyarisan Co., Ltd., and Takeda Pharmaceutical Co., Ltd. Tadakazu Hisamatsu has performed Joint Research with Alfresa Pharma Co., Ltd., and EA Pharma Co., Ltd.; received grant support from AbbVie GK, Boston Scientific Corp., EA Pharma Co., Ltd., JIMRO Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., and Takeda Pharmaceutical Co., Ltd., and received consulting and lecture fees from AbbVie GK, EA Pharma Co., Ltd., Janssen Research & Development, LLC., Gilead Sciences Inc., Eli Lilly and Co., Bristol Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Kissei Pharmaceutical Co., Ltd.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Miyoshi, J., Hisamatsu, T. Effect of maternal exposure to antibiotics during pregnancy on the neonatal intestinal microbiome and health. Clin J Gastroenterol 18, 1–10 (2025). https://doi.org/10.1007/s12328-024-02088-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-024-02088-6